BlackRock Inc. Invests $60.46 Million in 4D Molecular Therapeutics, Inc. $FDMT

Key Points

• BlackRock acquired 4.55 million shares of 4D Molecular Therapeutics in the second quarter, valued at approximately $60.46 million and representing an 8.70% stake. Institutional investors collectively own 99.27% of the company.
• Analyst sentiment is broadly positive, with a consensus rating of “Moderate Buy” and an average price target of $29.62. Targets from HC Wainwright and Goldman Sachs were $36 and $32, respectively, though one analyst downgraded the stock to “Sell.”
• 4D Molecular Therapeutics reported a quarterly loss of $1.04 per share, slightly worse than estimates, despite revenue of $3.78 million exceeding forecasts. Insiders sold approximately $2.22 million of stock during the quarter, while FDMT shares recently traded at $14.67.

BlackRock Inc. acquired a new stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 4,546,059 shares of the company's stock, valued at approximately $60,463,000. BlackRock Inc. owned approximately 8.70% of 4D Molecular Therapeutics at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Sei Investments Co. boosted its stake in 4D Molecular Therapeutics by 8.9% in the first quarter. Sei Investments Co. now owns 12,862 shares of the company's stock valued at $120,000 after acquiring an additional 1,050 shares during the last quarter. Martingale Asset Management L P lifted its stake in shares of 4D Molecular Therapeutics by 12.4% in the 4th quarter. Martingale Asset Management L P now owns 11,775 shares of the company's stock valued at $88,000 after purchasing an additional 1,303 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of 4D Molecular Therapeutics by 3.7% in the 3rd quarter. Dimensional Fund Advisors LP now owns 58,006 shares of the company's stock valued at $504,000 after purchasing an additional 2,069 shares during the period. Russell Investments Group Ltd. boosted its position in shares of 4D Molecular Therapeutics by 11.7% in the 2nd quarter. Russell Investments Group Ltd. now owns 21,816 shares of the company's stock worth $81,000 after purchasing an additional 2,284 shares during the last quarter. Finally, Prelude Capital Management LLC boosted its position in shares of 4D Molecular Therapeutics by 11.1% in the 3rd quarter. Prelude Capital Management LLC now owns 23,000 shares of the company's stock worth $200,000 after purchasing an additional 2,300 shares during the last quarter. 99.27% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. HC Wainwright reissued a "buy" rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a research note on Monday, July 20th. The Goldman Sachs Group reiterated a "buy" rating and issued a $32.00 target price on shares of 4D Molecular Therapeutics in a report on Thursday, August 13th. Chardan Capital raised shares of 4D Molecular Therapeutics to a "strong-buy" rating in a research report on Tuesday, July 28th. Wall Street Zen cut shares of 4D Molecular Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, May 9th. Finally, B. Riley Financial reissued a "buy" rating on shares of 4D Molecular Therapeutics in a report on Monday, August 17th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $29.62.

Insiders Place Their Bets

In other news, insider Scott Bizily sold 9,810 shares of the stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $12.00, for a total value of $117,720.00. Following the completion of the sale, the insider owned 8,617 shares of the company's stock, valued at approximately $103,404. This represents a 53.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider David Kirn sold 114,746 shares of the company's stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $10.47, for a total value of $1,201,390.62. Following the completion of the sale, the insider owned 942,485 shares in the company, valued at $9,867,817.95. The trade was a 10.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 198,574 shares of company stock valued at $2,220,985 over the last quarter. 7.90% of the stock is owned by corporate insiders.

4D Molecular Therapeutics Price Performance

Shares of FDMT opened at $14.67 on Monday. 4D Molecular Therapeutics, Inc. has a 52 week low of $5.97 and a 52 week high of $16.93. The firm has a market cap of $810.37 million, a P/E ratio of -5.58 and a beta of 2.73. The firm's 50-day simple moving average is $12.21 and its 200 day simple moving average is $10.34. The company has a debt-to-equity ratio of 0.05, a quick ratio of 8.03 and a current ratio of 8.03.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.02). 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. The company had revenue of $3.78 million during the quarter, compared to analyst estimates of $3.62 million. On average, analysts forecast that 4D Molecular Therapeutics, Inc. will post -4.09 earnings per share for the current year.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D's pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.

Want to see what other hedge funds are holding FDMT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source